9. Cyclin-Dependent kinase inhibitor as a potential novel therapeutic agent for pancreatic cancer

Abstract

BackgroundPancreatic cancer is the fourth leading cause of cancer death in Western societies and therapeutics are only modestly effective. Aberration of cell cycle regulation is seen in many cancers including pancreatic cancer. Selective inhibitor of cyclin-dependence kinase 4 and 6 (CDKi) is able to block phosphorylation of retinoblastoma to induce Gl arrest and prevent tumour growth. CDKi showed significant delay in progression free survival in the phase II clinical trial of breast cancer and is now in phase III trial. We hypothesise that a subgroup of pancreatic cancer will be sensitive to CDK4/6 inhibition.AimsWe aim to demonstrate the efficacy of CDKi in pancreatic cancer cell lines and..